Order Article Reprints

Chen J, Li Y, Wang H, Li T, Gu Y, Wang W, Shan Y, Yin J, Wang Y, Qin M, et al. Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial. Cancers. 2022; 14(19):4649. https://doi.org/10.3390/cancers14194649

Chen, Jiayu, Yan Li, Haiyuan Wang, Ting Li, Yu Gu, Wei Wang, Ying Shan, Jie Yin, Yongxue Wang, Meng Qin, and et al. 2022. "Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial" Cancers 14, no. 19: 4649. https://doi.org/10.3390/cancers14194649

Chen, J., Li, Y., Wang, H., Li, T., Gu, Y., Wang, W., Shan, Y., Yin, J., Wang, Y., Qin, M., Li, S., Pan, L., Peng, S., & Jin, Y. (2022). Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial. Cancers, 14(19), 4649. https://doi.org/10.3390/cancers14194649